Venetoclax-induced panniculitis in an acute myeloid leukemia patient

Liao, Po-Wei; Wang, Ren‐Ching; Chen, Tsung-Chih; Teng, Chieh‐Lin Jerry

doi:10.1007/s00277-020-04372-0

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While there have been scattered reports of ‘rash’ and ‘pruritus’ associated with venetoclax therapy, few analyses have included morphological clarification [8]. Isolated case studies have reported venetoclax-associated vitiligo [9,10], panniculitis [11], geographic tongue [12] and disseminated varicella zoster virus [13], respectively. On the other hand, no maculopapular drug eruptions have been described.…”

Section: Discussionmentioning

confidence: 99%

Pityriasiform drug eruption associated with venetoclax for acute myeloid leukaemia

Liu,

McMeniman

2024

Anti-Cancer Drugs

View full text Add to dashboard Cite

Venetoclax is a targeted antileukaemic therapy that has emerged as the primary treatment of acute myeloid leukaemia in patients of advanced age or who would otherwise be ineligible for standard chemotherapy. Despite the documented evidence of cutaneous side effects of venetoclax, few reports have clarified presenting cutaneous features beyond the descriptors ‘rash’ and ‘pruritus’. In this report, we describe the development of a pityriasiform drug eruption following venetoclax-based induction therapy for acute myeloid leukaemia. This study provides further evidence to characterise the range of cutaneous adverse events that are associated with venetoclax-based therapy. Further studies are needed to elucidate the epidemiology and pathophysiology of venetoclax-induced cutaneous toxicities.

show abstract